About This Video
On the Canadian Securities Exchange (CSE) Issuer Update series, hosted by James Black, InnoCan Pharma (CSE:INNO; OTCQB:INNPF) CEO Iris Bincovich and Scientific Advisor Dr. Joseph Pergolizzi discuss the company’s breakthrough in long-acting injectable synthetic CBD for chronic pain relief.
With a dual focus on wellness revenue and pharmaceutical innovation, InnoCan is developing a once-monthly CBD injection designed to provide sustained pain relief with fewer side effects. The company is also leveraging the 505(b)(2) regulatory pathway to accelerate development and exploring the veterinary market for additional applications.
Read the TranscriptAuto-generated by YouTube; names and terms may be misspelled.
welcome everyone this is James Black at the Canadian Securities Exchange this is an issue update with inan symbol I NN o on the csse and today I have the pleasure of being joined by Iris bovich CEO and Dr Joseph pitti who is also a scientific adviser to the company welcome to the show and thank you so much IR for joining us why don't you just start the proceedings today by
giving us a quick introduction of yourself and the company and then Joseph yourself after that thank you James so as stated inan is listed on the CSC I'm the CEO and one of the founders we have two major activity is our Wellness Revenue stream and our development of injectable synthetic CBD targeting a pain relief we have demonstrated a lot of Milestones over the years I think now
once we got the FDA a pathway 505 B2 which I'm sure Joe will elaborate we are in a promising routs to develop something new with less of side effect targeting very stable and safe and effective solution for chronic pain management H what what I learned along the years that partnership and working with the different collaboration status is the the major key of A Company Success we are very PR privileged to
work with the he University and professor bolds and with regulatory experts and Health Care Experts one of them is Joe so Joe the the stage is yours well thank you very much Iris and it's a pleasure to be here this morning I am a MD MBA I have been in the pharmaceutical drug development world for about 30 years now and I specialize on peroperative drugs and devices and
the development of them particularly analgesics so I've been involved with the majority of analgesics that are on the market in Canada the US and in Europe particularly the new ones and I'm really excited about this opportunity I agree a collaboration is very important particularly when you're developing such an important asset and this particular one really is you know chronic pain affects about onethird of the global population and it really depends on how
you define it you can Define it based on the duration of the pain and then you can further develop it and Define it based on the mechanism of action of that pain so it could come from a nerve it come from your joints from your muscles Etc it can be related to other things like cancer or diabetes and so unfortunately all of us at some point
in time in our life will experience pain and chronic pain is more than just experiencing pain it actually dehumanizes the individual decreases their quality of life and their activity of daily living and results in suffering and that's a big difference so when you look at what we're trying to develop we're looking at a long acting canono type of a drug and this would be a synthetic which allows us to really
explore the medicinal opportunities of this class of drugs and by providing it in a long long acting type of formulation what we call a liposomal formulation we may be able to apply it once a month so just think about that if you have chronic pain you're normally taking medications at least two or three times a day this could either be used once a month or in combination with
those so you could take less so it's really exciting because of the prevalence of pain globally yeah and I mean everyone knows about the opioid crisis and the relationship big Pharma has to the fact that these drugs are everywhere right fenol being one of the big problem generators here in our society in Canada at least from an addiction standpoint so I can I
appreciate what you guys are doing so maybe just taking a step back you've had a very busy year and let's talk about just the technology at a very base level how did you guys get to this point over the years of building a cannaboid or a platform this is work I know IRS you've been working on for years how did you guys get to this point
using this type of technology so we we notice the efficacy of CBD in pain reduced the challenge was the bioavailability or how the body absorbed because the the body actually destroy in the liver the CB and we were challenging ourselves how to deliver it in a very effective way and having you know the 100% active so incorporating this big molecule which
is not dissolve in in many solvents was quite a challenge we have several patent pending families to protect this development so loading this into an injection one injection that is being done once a month was challenging but it's I think it's a win-win you don't have to overdose yourself you don't have to use a lot of medicine it's a it's a very effective
we found out that by this injection you have a therapeutic level of CBD in the bloodstream a consist results we didn't see any side effects so Joe from your experience compared to Alternative Medicine what is your angle well there's a lot of excitement you know this class of drugs is presents a real great opportunity and the fact that we will be able to create a once- monthly injection just from a compliance
standpoint is really exciting and based on the preclinical work particularly in various animal species the excitement got even higher and what we were able to observe is that we could match blood levels with pain relief in these particular type of preclinical settings so we went forward to the United States FDA and we had a meeting with them and the first thing we asked is what pathway can we use for development and we were
advised that the 505 B2 p pathway which is leverages pre-existing information from other approved drugs would be suitable so that allows us to use that type of data that's already available to enhance our better understanding of how we can expeditiously develop this drug for humans so we have a a plan of action that takes us through the various stages of development starting with normal
healthy volunteers and then working all the way through different types of chronic pain situations these will include pain related to nerve what we call neuropathic pain it will also include what we call no susceptive pain and that's pain related to your muscles or joints and a broader Group which combines both called noop plastic pain we've reached out to some of the most prominent pain doctors in the world
and from different types of clinical settings not just the anesthesia pain doctors which are usually the last line of defense you know we're called the tertiary pain doctors but we also have U very prominent emergency room medicine doctors family doctors Rehabilitation and and the reason is because all of them are looking for a solution right now in the United States legislation that recently passed called the no pain act and this is
trying to explore the use of nonopioid analgesics and that's exactly where this drug would fall into so it's very important particularly for our older population and unfortunately you know around the globe we have an upside down patient population pyramid with more older patients than newer younger patients so this could present a great opportunity for some very common things like osteoarthritis and back pain I mean all of us will know somebody or
unfortunately in during the course of our life have some type of back pain osteoarthritis is is is globally prevalent and what we find is that the current medications either are limited in their effect iess or their safety and what we're going to try to do is develop this drug in a very safe and effective manner so that we can understand where it best works we just actually
finished a very interesting review of the clinical trials that are listed on the clinical trials.gov a us repository of various studies and I think we have a very clear path on what we can address from a chronic pain standpoint so a lot of excitement a real need and IT addresses some of the issues that you have already brought up that's a great overview you answer my
question about regulatory pathway obviously when you develop a molecule and a a treatment you're going to have to go through many steps with many governing bodies and go through trials so you mentioned all this in the context of humans but I I believe there's a Veterinary application as well to this to this te exactly as said we have a lot of experience in different species of
animal especially dogs you know after the covid just in the US 90 million people own the pet and it's it's a growing in Japan I heard that on every three dogs there is one baby so it's a growing market and they actually suffer from the same diseases as human especially very having hard time to walk climb stairs and different kinds of pain related issues we did several
clinical test on dogs and we saw High efficacy in those conditions and this is a great target market it has a lot of potential it's a win-win for the owners for the dogs themselves H one injection being administrated by the vet once a month so actually we are working parallel on both targets human application and the the veterinary market and we are really really exciting to pass the way for a
chronic painfree environment and world yeah I've had I've had back pain before and it's at its worst debilitating I also have an 18-year-old cat in the house so we could be doing this thing all day over here I'm going to throw back to you Joseph but I wanted to just go back to the no pain act I've never heard of this before obviously it's a us piece of
legislation but I assume that has something to do with trying to balance the scales of addressing pain in a population that is getting older but also on the other hand trying to mitigate the issue arising like I mentioned from the opioid opioid crisis so where do where do you see this technology this platform sort of being a part of this solution and how it's going to be how you're going to be
supported through this act or or navigate this act trying to get this product to a market well that's an excellent question and you know I applaud the US government and particularly the division of analgesic and anesthetic products at FDA when it comes to really reaching out and trying to find non-opioid analgesic options and this is one of those this is not a steroid this is not an opioid this
is not a non-al anti-inflammatory so it has a novel mechanism of action the cannaboid system has been described but not fully detailed as a omn neuromodulation Melo Davis and I wrote a couple papers years back about this so so it's very unique because this particular receptor modulates other receptors and how they respond and act at the same time it's a very primitive receptor canabo receptors
have been you know identified in in very primitive species and so this means that it provides an opportunity for us to really focus on a new pain pathway and medicinal marijuana we have to realize is not really regulated and so having a synthetic regulated product that people can rely on that has a standard of safety set by the FDA and efficacy measured and validated independently allows us to have more
confidence that it will work and it will work and be safe in the right population so with the no pain legislation they're looking for nonopiate analgesics particularly in the CMS or older population covered here in the United States but you could see how that translates globally because as I mentioned that population pyramid it is upside down now and I think one of the big things that I hear when I talk to
other pain experts out there and Other Drug developers is that the FDA is really looking to try to better understand this class of drugs they want to work with the companies and we had a very I think productive meeting with them they gave us great guidance so you know it's like any other drug development plan you know there are going to be ups and downs but it's definitely
worth because of the novelty and the ability to deliver it once a month yeah and I can't help but think of OIC as an example of a drug that's applied once a month people have gotten used to that but also the price point is obviously much higher than if it were a daily medication but I think there always the perception was that you know to make money off these drugs you have
to have you know keep filling people up with these bills and now people we popularize this once a month single injection methodology and I think that's encouraging for you guys now looking ahead to the upcoming year we just turned the the page into 2025 what are some of the Strategic strategic objectives you guys are striving for this here years and and maybe some of the hopes you have for
hitting Milestones so where we are you know on scale of scaling up the process taking this from after we got the FDA guidance from the lab to a scaleup preparing everything for FR in human this is the next in parallel we're doing the necessary test for the animal application just recently we have shared that for the second time we got a waiver from the
CVM Veterinary Center in the FDA regarding our Veterinary application so we are really encouraged from this and of course we see our Wellness subsidiary growing from quarter to quarter including new products and demonstrating revenues right and Dr Joseph any anything on your pathway this coming year that you want to share this year in 2025 we look forward to engaging further with the FDA it's Our intention also to put some
grants out there you know the NIH naida and other types of potential grants really should be team of experts that are looking at those non-diluted type of that also help validate the science we also are going to approach the grants from the standpoint of the Department of Defense here in the United States as well remember a lot of our soldiers and active military personnel do
experience pain back pain particularly if they're in combat or active duty and so this may be an option for them as well you brought up a great point though you know we're looking at things like the gp1s you mentioned one of them most epic by name and you know where's the the similarities you know by reducing weight you improve cardiovascular health you improve your health of your liver your
kidneys etc etc the the downstream beneficial health effects the same thing goes with pain when you are able to effectively address pain you increase functionality activities of daily living quality you improve sleep when you improve sleep you're functioning better during the day think about all of that and think about that potentially an impact on I mean unfortunately chronic lowback pain is very prevalent in people ages 45 through
60 right in that sweet spot of working so we're going to look at the literature we're going to data it more do some more Publications so that we can get alignment with the various stakeholders and the various stakeholders all benefit here not just the patient and their families right because if you're in chronic pain families your support system is also very much affected but the providers it'll give them an option
they need optionality there is no golden bullet that works in all pain patients all the time and finally the insurers and the providers if they're able to provide effective type of medications they can reduce it from a health economics and outcomes research standpoint and have a better type of outcomes and on their patient ining functionality maybe reducing burden of pills or other types of medications so we're going to look at that
so go forward with the da part we're going to seek out non- dilutional grants and funding from agencies like NIH we're going to be very active in data mining in the literature and talking with other key opinion leaders around the world that's awesome yeah I mean there's obviously a huge societal cost to pain it keeps people on the sideline it it burdens as you say many people around an
individual support structure and yeah I can I can see how and it's also mysterious I mean pain is very mysterious at times you don't know what What's going to cure something whether it's just time or or treatment so This research I'm sure is going to go very far into helping solve one of these great problems that we have as our population does get older irus
just quickly where where's the best place for people to get information about the company where do you want to direct them to the websites www inan pharma.com we active on LinkedIn and Twitter and Facebook we try to share the information but the website everything synchronized inside yeah you're very active on LinkedIn I noticed that and the company is also listed on the Canadian Securities Exchange symbol I NN
o this was an iser update with inam Pharma Iris bovich Dr Joseph pitti thank you so much for sharing your time today and we'll see you all soon



